Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin

[1]  A. Prentice,et al.  Hepcidin and the Iron-Infection Axis , 2012, Science.

[2]  F. Loreni,et al.  &agr;-Synuclein expression is modulated at the translational level by iron , 2012, Neuroreport.

[3]  Beate Ritz,et al.  α-Synuclein Genetic Variants Predict Faster Motor Symptom Progression in Idiopathic Parkinson Disease , 2012, PloS one.

[4]  B. Snively,et al.  Associations between Single Nucleotide Polymorphisms in Iron-Related Genes and Iron Status in Multiethnic Populations , 2011, PloS one.

[5]  A. Buil,et al.  Four variants in transferrin and HFE genes as potential markers of iron deficiency anaemia risk: an association study in menstruating women , 2011, Nutrition & metabolism.

[6]  D. Girelli,et al.  Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations , 2011, Journal of Medical Genetics.

[7]  B. Ritz,et al.  Occurrence of depression and anxiety prior to Parkinson's disease. , 2010, Parkinsonism & related disorders.

[8]  J. Vance,et al.  Gene-environment interactions in Parkinson's disease and other forms of parkinsonism. , 2010, Neurotoxicology.

[9]  J. T. Greenamyre,et al.  Mitochondrial iron metabolism and its role in neurodegeneration. , 2010, Journal of Alzheimer's disease : JAD.

[10]  M. Loriot,et al.  Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. , 2010, Archives of neurology.

[11]  M. Jimenez-Del-Rio,et al.  The Effects of Polyphenols on Survival and Locomotor Activity in Drosophila melanogaster Exposed to Iron and Paraquat , 2010, Neurochemical Research.

[12]  M. Kaps,et al.  Transcranial sonography for diagnosis of Parkinson's disease , 2010, BMC neurology.

[13]  Toshiko Tanaka,et al.  A genome-wide association analysis of serum iron concentrations. , 2010, Blood.

[14]  D. Nickerson,et al.  Genome-Wide Association Study Identifies Genetic Loci Associated with Iron Deficiency , 2009, PloS one.

[15]  T. Rouault,et al.  Brain iron homeostasis, the choroid plexus, and localization of iron transport proteins , 2009, Metabolic Brain Disease.

[16]  Ian H. Frazer,et al.  Common variants in TMPRSS6 are associated with iron status and erythrocyte volume , 2009, Nature Genetics.

[17]  C. Tzourio,et al.  Professional exposure to pesticides and Parkinson disease , 2009, Annals of neurology.

[18]  J. Connor,et al.  Iron, the substantia nigra and related neurological disorders. , 2009, Biochimica et biophysica acta.

[19]  J. Trojanowski,et al.  A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease , 2009, Neurobiology of Disease.

[20]  F. Mastaglia,et al.  Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease? , 2009, Movement disorders : official journal of the Movement Disorder Society.

[21]  B. Todorich,et al.  Oligodendrocytes and myelination: The role of iron , 2009, Glia.

[22]  N. Greig,et al.  Physiological and Pathological Role of Alpha-synuclein in Parkinson’s Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element , 2009, International journal of molecular sciences.

[23]  Leena Peltonen,et al.  Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. , 2009, American journal of human genetics.

[24]  B. Ritz,et al.  Genetics of iron regulation and the possible role of iron in Parkinson's disease , 2008, Neurobiology of Disease.

[25]  Marguerite Wieler,et al.  Midbrain iron content in early Parkinson disease , 2008, Neurology.

[26]  E. Morgan,et al.  Iron trafficking inside the brain , 2007, Journal of neurochemistry.

[27]  Peter Cloetens,et al.  Iron Storage within Dopamine Neurovesicles Revealed by Chemical Nano-Imaging , 2007, PloS one.

[28]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[29]  J. Andersen,et al.  Iron and Paraquat as Synergistic Environmental Risk Factors in Sporadic Parkinson's Disease Accelerate Age-Related Neurodegeneration , 2007, The Journal of Neuroscience.

[30]  J. Andersen,et al.  Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age , 2007, Neurobiology of Aging.

[31]  M. Elstner,et al.  Individual dopaminergic neurons show raised iron levels in Parkinson disease , 2007, Neurology.

[32]  K. Uğurbil,et al.  Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts , 2007, Movement disorders : official journal of the Movement Disorder Society.

[33]  S. Navas-Carretero,et al.  The G277S transferrin mutation does not affect iron absorption in iron deficient women , 2007, European journal of nutrition.

[34]  S. Henauw,et al.  Human transferrin G277S mutation and iron deficiency in pregnancy , 2006, British journal of haematology.

[35]  E. Tolosa,et al.  Association study of the G258S transferrin gene polymorphism and Parkinson's disease in the Spanish population , 2005, Journal of Neurology.

[36]  Tianhong Pan,et al.  Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. , 2005, Biochemical and biophysical research communications.

[37]  M. Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[38]  M. Mattson,et al.  Role of dietary iron restriction in a mouse model of Parkinson's disease , 2004, Experimental Neurology.

[39]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[40]  Christophe Tzourio,et al.  CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease , 2004, Annals of neurology.

[41]  E. Morgan,et al.  The significance of the mutated divalent metal transporter (DMT1) on iron transport into the Belgrade rat brain , 2003, Journal of neurochemistry.

[42]  P. Thong,et al.  Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. , 2003, Free radical biology & medicine.

[43]  J. Wall,et al.  Assessing the performance of the haplotype block model of linkage disequilibrium. , 2003, American journal of human genetics.

[44]  P. Aisen.  The g277s mutation in transferrin does not disturb function , 2003, British journal of haematology.

[45]  Subramanian Rajagopalan,et al.  Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.

[46]  Jean-Pierre Julien,et al.  Ceruloplasmin Regulates Iron Levels in the CNS and Prevents Free Radical Injury , 2002, The Journal of Neuroscience.

[47]  P. Silburn,et al.  The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients , 2002, Neuroscience Letters.

[48]  D. Schaid,et al.  Score tests for association between traits and haplotypes when linkage phase is ambiguous. , 2002, American journal of human genetics.

[49]  R. Benecke,et al.  Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease , 2002, Journal of Neural Transmission.

[50]  V. Uversky,et al.  Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. , 2001, The Journal of biological chemistry.

[51]  M. Daly,et al.  High-resolution haplotype structure in the human genome , 2001, Nature Genetics.

[52]  J. Graziano,et al.  Regulation of the 75-kDa Subunit of Mitochondrial Complex I by Iron* , 2001, The Journal of Biological Chemistry.

[53]  I. Izquierdo,et al.  Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits. , 2001, Parkinsonism & related disorders.

[54]  E. Beutler,et al.  Polymorphisms in the transferrin 5' flanking region associated with differences in total iron binding capacity: possible implications in iron homeostasis. , 2001, Blood cells, molecules & diseases.

[55]  Kazuhiro Iwai,et al.  Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice , 2001, Nature Genetics.

[56]  D. Duffy,et al.  Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. , 2000, American journal of human genetics.

[57]  D. Maraganore,et al.  Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990 , 1999, Neurology.

[58]  P Z Marmarelis,et al.  MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. , 1999, Magnetic resonance imaging.

[59]  E. Morgan,et al.  Expression of the neuronal transferrin receptor is age dependent and susceptible to iron deficiency , 1998, The Journal of comparative neurology.

[60]  H. G. Kim,et al.  Manganese: A transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of Parkinsonism , 1998, Neuroscience.

[61]  R. Ordidge,et al.  Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease , 1995, Neurology.

[62]  G Becker,et al.  Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography , 1995, Neurology.

[63]  C. Morris,et al.  Iron histochemistry of the substantia nigra in Parkinson's disease. , 1994, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[64]  Y. Agid,et al.  Distribution of 125I‐Ferrotransferrin Binding Sites in the Mesencephalon of Control Subjects and Patients with Parkinson's Disease , 1993, Journal of neurochemistry.

[65]  C. Olanow,et al.  Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers , 1993, Journal of neuroscience research.

[66]  D. Ben-shachar,et al.  Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats , 1991, Journal of neurochemistry.

[67]  P Riederer,et al.  Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.

[68]  C. Marsden,et al.  INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.

[69]  J. Dankert,et al.  PENICILLIN-SENSITIVE STREPTOCOCCAL ENDOCARDITIS , 1982, The Lancet.

[70]  K. Brew,et al.  The complete amino acid sequence of human serum transferrin. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[71]  Hollis G. Potter,et al.  Author Manuscript , 2013 .

[72]  J. Andersen.  Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson’s disease , 2009, Neurotoxicity Research.

[73]  P. Riederer,et al.  Potential sources of increased iron in the substantia nigra of parkinsonian patients. , 2006, Journal of neural transmission. Supplementum.

[74]  Dana C Crawford,et al.  Definition and clinical importance of haplotypes. , 2005, Annual review of medicine.

[75]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[76]  P. Riederer,et al.  Intranigral injected iron progressively reduces striatal dopamine metabolism , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[77]  B. Ritz,et al.  American Journal of Epidemiology Original Contribution Parkinson's Disease and Residential Exposure to Maneb and Paraquat from Agricultural Applications in the Central Valley of California , 2022 .